| Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy R Seiler, HAD Ashab, N Erho, BWG van Rhijn, B Winters, J Douglas, ... European urology 72 (4), 544-554, 2017 | 800 | 2017 |
| The long noncoding RNA SChLAP1 promotes aggressive prostate cancer and antagonizes the SWI/SNF complex JR Prensner, MK Iyer, A Sahu, IA Asangani, Q Cao, L Patel, IA Vergara, ... Nature genetics 45 (11), 1392-1398, 2013 | 741 | 2013 |
| Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy N Erho, A Crisan, IA Vergara, AP Mitra, M Ghadessi, C Buerki, ... PloS one 8 (6), e66855, 2013 | 682 | 2013 |
| The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer D Chakravarty, A Sboner, SS Nair, E Giannopoulou, R Li, S Hennig, ... Nature communications 5 (1), 5383, 2014 | 611 | 2014 |
| Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition V Evdokimova, C Tognon, T Ng, P Ruzanov, N Melnyk, D Fink, A Sorokin, ... Cancer cell 15 (5), 402-415, 2009 | 553 | 2009 |
| Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study E Lalonde, AS Ishkanian, J Sykes, M Fraser, H Ross-Adams, N Erho, ... The lancet oncology 15 (13), 1521-1532, 2014 | 393 | 2014 |
| Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population RJ Karnes, EJ Bergstralh, E Davicioni, M Ghadessi, C Buerki, AP Mitra, ... The Journal of urology 190 (6), 2047-2053, 2013 | 357 | 2013 |
| Identification of a PAX-FKHR gene expression signature that defines molecular classes and determines the prognosis of alveolar rhabdomyosarcomas E Davicioni, F Graf Finckenstein, V Shahbazian, JD Buckley, TJ Triche, ... Cancer research 66 (14), 6936-6946, 2006 | 331 | 2006 |
| Molecular classification of rhabdomyosarcoma—genotypic and phenotypic determinants of diagnosis: a report from the Children's Oncology Group E Davicioni, MJ Anderson, FG Finckenstein, JC Lynch, SJ Qualman, ... The American journal of pathology 174 (2), 550-564, 2009 | 309 | 2009 |
| Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy SG Zhao, SL Chang, N Erho, M Yu, J Lehrer, M Alshalalfa, C Speers, ... JAMA oncology 3 (12), 1663-1672, 2017 | 280 | 2017 |
| RNA biomarkers associated with metastatic progression in prostate cancer: a multi-institutional high-throughput analysis of SChLAP1 JR Prensner, S Zhao, N Erho, M Schipper, MK Iyer, SM Dhanasekaran, ... The lancet oncology 15 (13), 1469-1480, 2014 | 273 | 2014 |
| Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate-and high-risk men AE Ross, MH Johnson, K Yousefi, E Davicioni, GJ Netto, L Marchionni, ... European urology 69 (1), 157-165, 2016 | 269 | 2016 |
| Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy RB Den, K Yousefi, EJ Trabulsi, F Abdollah, V Choeurng, FY Feng, ... Journal of Clinical Oncology 33 (8), 944-951, 2015 | 239 | 2015 |
| Individual patient-level meta-analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease DE Spratt, K Yousefi, S Deheshi, AE Ross, RB Den, EM Schaeffer, ... Journal of Clinical Oncology 35 (18), 1991-1998, 2017 | 228 | 2017 |
| Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort MR Cooperberg, E Davicioni, A Crisan, RB Jenkins, M Ghadessi, ... European urology 67 (2), 326-333, 2015 | 225 | 2015 |
| Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis SG Zhao, SL Chang, DE Spratt, N Erho, M Yu, HAD Ashab, M Alshalalfa, ... The lancet oncology 17 (11), 1612-1620, 2016 | 223 | 2016 |
| FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes EJ Adams, WR Karthaus, E Hoover, D Liu, A Gruet, Z Zhang, H Cho, ... Nature 571 (7765), 408-412, 2019 | 218 | 2019 |
| A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy … EA Klein, K Yousefi, Z Haddad, V Choeurng, C Buerki, AJ Stephenson, ... European urology 67 (4), 778-786, 2015 | 205 | 2015 |
| Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer DE Spratt, J Zhang, M Santiago-Jiménez, RT Dess, JW Davis, RB Den, ... Journal of Clinical Oncology 36 (6), 581-590, 2018 | 202 | 2018 |
| The homeoprotein six1 transcriptionally activates multiple protumorigenic genes but requires ezrin to promote metastasis Y Yu, E Davicioni, TJ Triche, G Merlino Cancer research 66 (4), 1982-1989, 2006 | 196 | 2006 |
Nicholas ErhoResearch Science Manager, Amazon AlexaVerified email at amazon.com
